Compare CENX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENX | FOLD |
|---|---|---|
| Founded | 1995 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aluminum | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 1996 | 2007 |
| Metric | CENX | FOLD |
|---|---|---|
| Price | $30.78 | $9.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $33.00 | $30.29 |
| AVG Volume (30 Days) | 2.6M | ★ 4.6M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $2,525,100,000.00 | $598,704,000.00 |
| Revenue This Year | $16.07 | $21.12 |
| Revenue Next Year | N/A | $21.23 |
| P/E Ratio | $37.06 | ★ N/A |
| Revenue Growth | 20.15 | ★ 21.28 |
| 52 Week Low | $13.05 | $5.51 |
| 52 Week High | $34.52 | $10.57 |
| Indicator | CENX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.86 | 64.67 |
| Support Level | $25.40 | $9.56 |
| Resistance Level | $30.19 | $10.05 |
| Average True Range (ATR) | 1.30 | 0.37 |
| MACD | 0.32 | -0.02 |
| Stochastic Oscillator | 90.20 | 51.14 |
Century Aluminum Co produces primary aluminum standard grade and value-added products. The firm operates smelter facilities in the United States and Iceland. The majority of revenue is generated from Glencore, which agreed to purchase nearly all of Century Aluminum's North American production. Century purchases nearly all of its alumina from Glencore. The company produces high purity aluminum, standard-grade aluminum sow and tee bars, and value-added billet and foundry products. Century also owns a carbon anode production facility in the Netherlands.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.